Additional information
Yellow Powder
949916-82-9
ACI-020820
>300°C
C11H9N5
211.22
Ambient
2-8°C
ocular hypertension
Pharmaceutical Impurity Standards
9,10-Dihydro-7H-imidazo[2',1':2,3]imidazo[4,5-f]quinoxaline
9,10-Dihydro-7H-imidazo[2',1':2,3]imidazo[4,5-f]quinoxaline
7H-Imidazo[1?,2?:1,2]imidazo[4,5-c]-1,5-naphthyridine, 9,10-dihydro;3,8,11,13,16-Pentaazatetracyclo[8.6.0.0[2,7].0[12,16]]hexadeca-1(10),2,4,6,8,11-hexaene





![sec-BUTYL PACLITAXEL (25 mg) ((2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-Bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (αR,βS)-α-hydroxy-β-[[(2S)-2-methyl-1-oxobutyl]amino]benzenepropanoate)](https://analyticachemie.in/wp-content/uploads/uspimage-1.jpg)